evaluated for their anti-HCV activity. Herein we report the synthesis, structure–activity relationships (SARs), and pharmacokinetic properties of this new class of thiourea compounds that showed potent inhibitory activities against HCV in the cell-based subgenomic HCV replicon assay. Among compounds tested, the fluorene compound 4b was found to possess the most potent activity (EC50 = 0.3 μM), lower cytotoxicity
This invention relates to thiourea compounds of formula (II) shown below:
Each variable in formula (I) is defined in the specification. These compounds can be used to treat hepatitis C virus infection.